3 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow Bioniz Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL BNZ132-1-40 - LGL Leukemia, CTCL | Phase 1 / Phase 2 | Completed | Bioniz Therapeutics | 50 | 2018-04-01 | 2021-05-25 |
| A Multiple-Dose Study of Intravenous BNZ132-1-40 in Healthy Adult Subjects BNZ132-1-40, Placebo - Safety and Tolerability in Healthy Subjects | Phase 1 | Completed | Bioniz Therapeutics | 32 | 2017-10-30 | 2018-05-15 |
| A First-in-Human Study of BNZ132-1-40 BNZ132-1-40 - Healthy | Phase 1 | Completed | Bioniz Therapeutics | 18 | 2016-11-01 | 2017-06-22 |
Leukemia, Large Granular Lymphocytic (1)
United States (3)
Paul A Frohna, MD, PhD (2) · Jonathan Brammer, MD, PhD (1)